特维斯生物科学
TWST
132.75
-11.74
-8.13%
特维斯生物科学
US · TWST
#1258 按市值排名
上市于 2018
132.75
-11.74
-8.13%
实时 - 追踪5344个代码 - 心跳于265秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量增加了3家。
- 机构持股总比例上升了2.2个百分点。
机构持股
- 机构持股比例
- 126.88% +2.18pp
- 机构数量
- 406 +3
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund103.39%
Hedge Fund14.83%
Public Company4.94%
Private Company1.65%
Government Pension Fund1.38%
Individual/Insider1.31%
Insurance Company0.54%
主要股东 截至 2026-08-31
FMR
13.97% · 8.76M 股
BlackRock
9.30% · 5.83M 股
Artisan Partners Limited Partnership
7.66% · 4.80M 股
T. Rowe Price Group, Inc.
6.75% · 4.23M 股
ARK Investment Management LLC
5.40% · 3.39M 股
State Street Global Advisors
5.15% · 3.23M 股
Vanguard Capital Management, LLC
5.01% · 3.14M 股
Vanguard Portfolio Management, LLC
4.51% · 2.82M 股
William Blair Investment Management, LLC
4.16% · 2.61M 股
EdgePoint Investment Group Inc.
4.02% · 2.52M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 0次买入 · 50次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Emily Leproust | Chairperson & CEO | 0.51% |
| Paula Green | Officer | 0.17% |
| Keith Crandell | Independent Director | 0.17% |
| Patrick Finn | President | 0.11% |
| Robert Chess | Lead Independent Director | 0.10% |
| Adam Laponis | Chief Financial Officer | 0.05% |
| Nelson Chan | Independent Director | 0.04% |
| Robert Ragusa | Independent Director | 0.04% |
| Dennis Cho | Senior VP, General Counsel, Secretary and Chief Ethics & Compliance Officer | 0.03% |
| Katryn Blake | Director | 0.03% |
| Melissa Starovasnik | Independent Director | 0.03% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-10-04 | Emily Leproust | Chairperson & CEO | Intent to Sell (Form 144) | -4,548 | $202.15 |
| 2026-10-01 | Emily Leproust | Chairperson & CEO | Open Market Disposition | -45,736 | $188.88 |
| 2026-10-01 | Robert Werner | Chief Accounting Officer | Open Market Disposition | -1,482 | $188.88 |
| 2026-10-01 | Patrick Finn | President | Open Market Disposition | -25,714 | $188.88 |
| 2026-10-01 | Paula Green | Officer | Open Market Disposition | -10,088 | $188.88 |
| 2026-10-01 | Adam Laponis | Chief Financial Officer | Open Market Disposition | -8,057 | $188.88 |
| 2026-10-01 | Dennis Cho | Senior VP, General Counsel, Secretary and Chief Ethics & Compliance Officer | Open Market Disposition | -9,514 | $188.88 |
| 2026-09-30 | Emily Leproust | Chairperson & CEO | Automatic Disposition | -655 | $200.00 |
| 2026-09-23 | Emily Leproust | Chairperson & CEO | Automatic Disposition | -5,203 | $175.23–184.60 |
| 2026-09-20 | Emily Leproust | Chairperson & CEO | Open Market Disposition | -1,687 | $165.49 |
| 2026-09-20 | Paula Green | Officer | Open Market Disposition | -294 | $165.49 |
| 2026-09-20 | Dennis Cho | Senior VP, General Counsel, Secretary and Chief Ethics & Compliance Officer | Open Market Disposition | -348 | $165.49 |
| 2026-09-16 | Emily Leproust | Chairperson & CEO | Automatic Disposition | -147,838 | $158.09–163.39 |
| 2026-09-16 | Emily Leproust | Chairperson & CEO | Derivative Exercise and Sale | -208,708 | $8.82–158.09 |
| 2026-09-07 | Emily Leproust | Chairperson & CEO | Open Market Disposition | -2,302 | $122.62 |
| 2026-09-07 | Robert Werner | Chief Accounting Officer | Open Market Disposition | -238 | $122.62 |
| 2026-09-07 | Paula Green | Officer | Open Market Disposition | -907 | $122.62 |
| 2026-09-07 | Dennis Cho | Senior VP, General Counsel, Secretary and Chief Ethics & Compliance Officer | Open Market Disposition | -412 | $122.62 |
| 2026-08-24 | Emily Leproust | Chairperson & CEO | Automatic Disposition | -41,570 | $150.56–154.45 |
| 2026-08-23 | Robert Werner | Chief Accounting Officer | Open Market Disposition | -1,523 | $139.07–140.77 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:27 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
特维斯生物科学 讨论区 0 条评论